학술논문

Prescription Benzodiazepine Use Among Older Adults
Document Type
article
Source
Harvard Review of Psychiatry. 26(5)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Clinical Trials and Supportive Activities
Behavioral and Social Science
Clinical Research
Acquired Cognitive Impairment
Neurosciences
Mental Health
Aging
Brain Disorders
6.1 Pharmaceuticals
6.6 Psychological and behavioural
Evaluation of treatments and therapeutic interventions
Mental health
Good Health and Well Being
Aged
Aged
80 and over
Anxiety Disorders
Behavioral Symptoms
Benzodiazepines
Dementia
Drug Prescriptions
Humans
Middle Aged
Sleep Initiation and Maintenance Disorders
anxiety
behavioral and psychological symptoms of dementia
benzodiazepine
insomnia
older adults
Psychology
Cognitive Sciences
Psychiatry
Clinical sciences
Language
Abstract
ObjectivesDespite evidence for many potential risks, use of benzodiazepines (BZDs) among older adults is common. The authors evaluated the available evidence for BZD effectiveness and tolerability for use in older adults in three psychiatric conditions for which BZDs are commonly prescribed: insomnia, anxiety disorders, and behavioral and psychological symptoms of dementia.DesignElectronic databases, including PubMed/MEDLINE, were searched to identify articles that (1) included patients ≥50 years of age, (2) focused on patients diagnosed with insomnia, anxiety disorders, or behavioral and psychological symptoms of dementia, and (3) were either a randomized, placebo-controlled trial or a randomized trial comparing a BZD with either another psychotropic medication or psychotherapy.ResultsThirty-one studies met the inclusion criteria. Of the three clinical indications evaluated, treatment of insomnia had the greatest available evidence for use of BZDs among older adults, with 21 of 25 trials demonstrating improved sleep outcomes with use of BZDs. Only one trial was found to meet eligibility criteria for BZD use in anxiety disorders, demonstrating benefit over placebo. Five studies for use in behavioral disturbances in dementia were included, of which only one demonstrated improvement over placebo.ConclusionThis systematic review suggests that BZD prescribing to older adults is significantly in excess of what the available evidence suggests is appropriate. Future trials should focus on efforts to reduce both acute and chronic BZD use among older adults while improving access to effective non-pharmacologic treatment alternatives.